EASL Policy Dialogues episodes are short videos on topical health policy issues, combining a scientific perspective and a policy perspective from two experts.

The episodes aim to showcase the policy stakes at the European and global level for liver health.

The Policy Dialogues will be used to raise awareness on EASL’ advocacy priorities and actions to engage the hepatology community, policy makers, and the public.

The EASL Policy Dialogues are supported by CymaBay, Gilead, Bayer, Boehringer Ingelheim, Echosens, Grifols and Novo Nordisk. CymaBay, Gilead, Bayer, Boehringer Ingelheim, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.